#bostongene

BostonGene will present its latest AI foundation models at the 22nd Annual RadMed Symposium, highlighting how multimodal AI and blood-based immune profiling are helping predict immunotherapy response, assess toxicity risk, and improve patient stratification. The session will demonstrate how AI-driven insights can accelerate precision oncology research and support smarter drug development.

As drug development becomes increasingly complex, the need for more informed decision-making has never been greater. By leveraging multimodal AI and advanced biological modeling, organizations can gain deeper insights into disease mechanisms, optimize patient selection and improve clinical trial design.

Integrating genomic, clinical, immune and imaging data enables researchers to move beyond retrospective analysis and make more predictive, data-driven decisions earlier in the development process. This approach has the potential to reduce risk, improve trial outcomes and accelerate the delivery of innovative therapies to patients.

Industry recognition continues to highlight the growing role of AI in transforming oncology research and reshaping the future of precision medicine.

BostonGene will present six research abstracts at EHA 2026, highlighting how AI-powered multiomics analysis and immune profiling are transforming blood cancer research. Developed in collaboration with leading cancer centers and academic institutions, these studies demonstrate the potential of predictive modeling, biomarker discovery, and integrated genomic analysis to improve risk stratification, predict treatment response, and support more personalized therapeutic strategies. The findings reinforce the growing role of AI in advancing precision medicine and optimizing clinical decision-making in hematologic malignancies.

BostonGene is showcasing new research at ASCO 2026 that demonstrates the clinical value of AI-powered models and comprehensive molecular profiling in oncology. The presented studies highlight innovative approaches to biomarker discovery, treatment response prediction, and patient stratification, helping advance precision medicine and improve outcomes across multiple cancer types.

A new research collaboration between academia and AI-driven technology is helping advance precision oncology by combining molecular, genomic and immune profiling insights to support more personalized cancer treatment approaches. The initiative focuses on transforming complex clinical and biological data into actionable insights that can help improve therapeutic decision-making and support future oncology research.

BostonGene has received recognition from Frost & Sullivan for its contribution to AI-driven oncology innovation. The company’s multimodal platform supports biopharma teams by analyzing complex biological and clinical data to improve trial design, biomarker strategies, and patient selection in cancer treatment research.

The recognition reflects the growing role of AI and data-driven technologies in helping researchers make faster and more informed decisions throughout the drug development process.

BostonGene and Unilever are working together to explore how AI and multiomics can support scientific research and deepen the understanding of human biology. The collaboration combines data integration, analytics, and scientific expertise to study biological variation and identify insights that may contribute to future consumer research and product development. It also highlights the increasing use of AI in broader areas of scientific exploration and innovation.

BostonGene is working with ImmunoGenesis to study IMGS-001, a therapy under evaluation in the NCT06014502 trial for solid tumors. The collaboration uses AI-based multiomic analysis and spatial biology to examine how treatments interact with both tumors and the immune system. By focusing on detailed biological data from individual patients, the research aims to improve understanding of treatment response and support more informed clinical decisions.